Jennifer R. Brown, MD, PhD, on ALPINE Data, CLL Highlights at ASH 2022

By Jennifer R. Brown, MD, PhD - Last Updated: December 20, 2022

Blood Cancers Today caught up with the Society of Hematologic Oncology President Jennifer R. Brown, MD, PhD, to find out what she was watching at the 64th American Society of Hematology Annual Meeting. Dr. Brown highlighted data from the phase III ALPINE study, which compared zanubrutinib with ibrutinib as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

 

Post Tags:ASH22
Advertisement
Advertisement
Advertisement
Editorial Board